Gate Bioscience Secures $65M Series B Round Led by Forbion and Eli Lilly

Why It Matters

The capital infusion validates Gate Bioscience’s novel protein‑targeting platform and accelerates its path to clinic, potentially reshaping drug discovery for inflammatory and neurological diseases. Participation by a major pharma player like Eli Lilly signals industry confidence and could spur further collaborations.

Deal Summary

Gate Bioscience, a California biotech firm, announced a $65 million Series B financing. The round was led by Forbion with participation from Eli Lilly, Versant Ventures, Andreessen Horowitz Bio + Health, GV, ARCH Venture Partners and existing backers. The capital will advance its molecular gate programs into clinical trials.